DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • May 5th, 2014 • Agile Therapeutics Inc • Pharmaceutical preparations • New York
This Development, License and Commercialization Agreement (this “Agreement”) is entered into as of October 18, 2006 (the “Effective Date”) between Corium International, Inc., a Delaware corporation having its principal place of business at 2686 Middlefield Road, Redwood City, CA 94063, (“Corium”), and Agile Therapeutics, Inc., a Delaware corporation, having its principal place of business at 366 Wall Street, Princeton, NJ 08540, (“Agile”).
Text omitted and filed separately with the Securities and Exchange Commission/Confidential Treatment Requested under 17 C.F.R. Section 240.24b-2Development, License and Commercialization Agreement • December 26th, 2018 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into and effective as of December 18, 2018 (the “Effective Date”) by and between Endo Ventures Limited, an Irish company, with offices located at First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland (“EVL”), and Catalyst Pharmaceuticals, Inc., a Delaware corporation, with offices located at 355 Alhambra Circle Suite 1250, Coral Gables, FL, USA (“Catalyst”).
DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • November 9th, 2007 • Sepracor Inc /De/ • Pharmaceutical preparations • New York
This DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”) is entered into between Sepracor Inc., a company organized under the laws of the State of Delaware, United States, and having its principal place of business at 84 Waterford Drive, Marlborough, MA 01752-7010, United States, and Glaxo Group Limited, a company organized under the laws of England & Wales and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”).
DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT by and between INDEVUS PHARMACEUTICALS, INC. and TEVA PHARMACEUTICAL INDUSTRIES LTD.Development, License and Commercialization Agreement • December 11th, 2008 • Indevus Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made as of September 25, 2008 (“Agreement Date”), by and between INDEVUS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 33 Hayden Avenue, Lexington, MA 02421, United States (“Indevus”) and TEVA PHARMACEUTICAL INDUSTRIES LTD., a limited liability company existing under the laws of Israel and having its principal office at Petah Tiqva 49131, Israel (“Teva”).
AMENDMENT NO. 6 TO DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • April 7th, 2011 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 6 (“Amendment No. 6”) to the Development, License and Commercialization Agreement is made and effective as of the 6th day of April, 2011 (“Amendment Effective Date”) between Idenix Pharmaceuticals, Inc., with offices at 60 Hampshire Street, Cambridge Massachusetts 02139, USA (“Idenix US”), Idenix (Cayman) Limited with offices c/o Walkers SPV Limited, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands (“Idenix Cayman” and together with Idenix US, “Idenix”) and Novartis Pharma AG with offices at Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novartis”).
Redacted portions are indicated by [****]. DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT Dated May 13, 2005 By and Between BioMarin Pharmaceutical Inc. And Ares Trading S.A.,Development, License and Commercialization Agreement • July 6th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
This DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (“Agreement”) is made effective as of the 13th day of May, 2005 (the “Effective Date”) by and between BioMarin Pharmaceutical Inc., a corporation organized under the laws of Delaware and having its principal place of business at 105 Digital Drive, Novato, California 94949 (“BioMarin”) and Ares Trading S.A., a corporation organized under the laws of Switzerland and having a principal place of business at Zone Industrielle de l’Ouriettaz, 1170 Aubonne, Switzerland (“Serono”). BioMarin and Serono are each referred to herein as a “Party” and collectively as the “Parties”.
Designates portions of this document have been omitted pursuant to a request for confidential treatment filed separately with the Commission] DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • August 15th, 2016 • Adamis Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into on May 9, 2016 (the “Effective Date”), by and between Watson Laboratories, Inc., a Nevada corporation (“Watson”), on the one hand, and Adamis Pharmaceuticals Corporation, a company incorporated under the laws of Delaware (“Adamis”), on the other hand. Watson and Adamis shall each sometimes be referred to herein as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 5 TO DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENTDevelopment, License and Commercialization Agreement • February 6th, 2009 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 5 (“Amendment No. 5”) to the Development, License and Commercialization Agreement is made and effective as of the 23 day of January, 2009 (“Amendment Effective Date”) between Idenix Pharmaceuticals, Inc., with offices at 60 Hampshire Street, Cambridge Massachusetts 02139, USA (“Idenix US”), Idenix (Cayman) Limited with offices c/o Walkers SPV Limited, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands (“Idenix Cayman” and together with Idenix US, “Idenix”) and Novartis Pharma AG with offices at Forum 1, Novartis Campus, 4056 Basel, Switzerland (“Novartis”).
